Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat

Stock Track

8小時前

Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.

The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.

These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1181983787"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181983787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181983787?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181983787","market":"sg","top_or_hot":-1,"title":"Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.</p><p>These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-11 08:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.</p><p>These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1181983787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181983787","pubTimestamp":1778457828,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.The movement was fueled by encouraging...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股赛道|Moderna夜盘大涨6.31%疫苗数据强劲营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}